Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial
| Autor: | Tine A. Bækdal, Kjeld Hermansen, Lene S. Mortensen, Anna Pietraszek, M. During, Anne Flint, H Jørgensen |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Denmark Endocrinology Diabetes and Metabolism Cmax Hyperlipidemias Type 2 diabetes Diet High-Fat Placebo Body Mass Index chemistry.chemical_compound Endocrinology Double-Blind Method Glucagon-Like Peptide 1 Risk Factors Germany Internal medicine Internal Medicine medicine Humans Hypoglycemic Agents Obesity Aged Hypolipidemic Agents Cross-Over Studies Gastric emptying Triglyceride business.industry Liraglutide Middle Aged Postprandial Period medicine.disease Lipids Crossover study Postprandial Diabetes Mellitus Type 2 Gastric Emptying chemistry Cardiovascular Diseases Female business Half-Life medicine.drug |
| Zdroj: | Hermansen, K, Baekdal, T A, Düring, M, Pietraszek, A, Mortensen, L S, Jørgensen, H & Flint, A 2013, ' Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes : a randomized, double-blind, placebo-controlled, cross-over trial ', Diabetes, Obesity and Metabolism . https://doi.org/10.1111/dom.12133 |
| ISSN: | 1463-1326 1462-8902 |
| Popis: | Aims Postprandial triglyceridaemia is a risk factor for cardiovascular disease (CVD). This study investigated the effects of steady-state liraglutide 1.8 mg versus placebo on postprandial plasma lipid concentrations after 3 weeks of treatment in patients with type 2 diabetes mellitus (T2DM). Methods In a cross-over trial, patients with T2DM (n = 20, 18–75 years, BMI 18.5–40 kg/m2) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo. After each 3-week period, a standardized fat-rich meal was provided, and the effects of liraglutide on triglyceride (primary endpoint AUC0–8h), apolipoprotein B48, non-esterified fatty acids, glycaemic responses and gastric emptying were assessed. ClinicalTrials.gov ID: NCT00993304. Funding: Novo Nordisk A/S. Results After 3 weeks, mean postprandial triglyceride (AUC0–8h liraglutide/placebo treatment-ratio 0.72, 95% CI [0.62–0.83], p = 0.0004) and apolipoprotein B48 (AUC0–8h ratio 0.65 [0.58–0.73], p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text